mFOLFOX in Second-Line Biliary Tract Cancer: ABC-06 Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
At the ASCO 2019 Annual Meeting held in Chicago, researchers presented the findings of the ABC-06 Phase 3 clinical trial. This study evaluated the efficacy and safety of adding mFOLFOX chemotherapy to active symptom control (ASC) as a second-line treatment for patients with advanced biliary tract cancer (BTC) who had progressed on Gemcitabine and Cisplatin.
Study Design: ABC-06 Trial
The trial randomized 162 patients who had failed first-line therapy into two groups:
- ASC Group (N=81): Active symptom control alone.
- ASC + mFOLFOX Group (N=81): ASC plus mFOLFOX chemotherapy (Oxaliplatin 85 mg/m², L-folinic acid 175 mg/m², 5-FU 400 mg/m² bolus, followed by 5-FU 2,400 mg/m² 46-hour infusion every two weeks).
The primary endpoint was overall survival (OS).
Key Survival Results
The addition of mFOLFOX provided a statistically significant improvement in survival:
- Median Overall Survival: 6.2 months for the ASC + mFOLFOX group vs. 5.3 months for the ASC group.
- Survival Rates:
- 6-Month OS: 50.6% (ASC+mFOLFOX) vs. 35.5% (ASC).
- 12-Month OS: 25.9% (ASC+mFOLFOX) vs. 11.4% (ASC).
- Hazard Ratio (Adjusted): 0.69, indicating a significant survival benefit for the combination group.
Efficacy and Safety
- Progression-Free Survival (PFS): 4.0 months in the mFOLFOX group.
- Disease Control Rate: 33% in the mFOLFOX group.
- Safety: Adverse events were higher in the mFOLFOX group (59% vs. 40%). Common side effects included fatigue (19%), neutropenia (12%), and infection (18%).
Conclusion
Dr. Thomas Yau and the ABC-06 investigators concluded that adding mFOLFOX to ASC significantly improves overall survival in patients with advanced biliary tract cancer who have failed first-line Gemcitabine and Cisplatin. This trial establishes mFOLFOX as a new standard-of-care option for second-line therapy in advanced BTC.
Source: ASCO 2019 - ABC-06 Trial Abstract No: 4003
#BiliaryTractCancer #Cholangiocarcinoma #mFOLFOX #ABC06 #ASCO2019 #CancerResearch #SecondLineTherapy
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6